Get Flash to see the Connected Social Media Player, or click here for media file.

It’s August 2009 and in the last 12 months, Lou Bock’s portfolio has had some impressive success. He talks about how Zogenix, Horizon Therapeutics, Somaxon, Prestwick Pharmaceuticals and Orexigen have all done well. The Scale Venture Partners Managing Director has seen two positive Phase III outcomes, 2 FDA approvals and one progressing to approval since August 2008.

Related posts:

1. Lou Bock’s Thoughts on Venture Investing Capital efficiency and regulatory hurdles are the two main challenges for investing in healthcare today. Scale Venture Partners Managing Director, Lou Bock shares these insights as well as discussing what is most important to him in an investment today. ...
2. Success in Mark Brook’s Healthcare Services and Medical Devices Portfolio The last 12 months have been good for Scale Venture Partners‘ Managing Director Mark Brooks . As an investor in healthcare services, and medical devices, Mark delves into his successes, and speaks to his current investments and their bright future....
3. An Embeddable Content Platform for Rapid Application Development: Geoffrey Bock on Documentum Content Server OEM Edition In this podcast, hear industry analyst Geoffrey Bock, principal of Bock and Company, discuss the business case behind developing content-rich applications. The challenge of rapid application development is finding the right starting point — delivering the innovative, comprehensive, (and elegantly...
4. Looking for Investments at CES Jim Jones is a managing director at Scale Venture Partners, a venture capital firm which invests in emerging tech and healthcare companies. Jim’s focus is on semiconductors and consumer electronics, so we met with him last week at CES to...
5. Venture Capital Today From Sharon Wienbar Scale Venture Partners Managing Director, Sharon Wienbar gives listeners her perspective on life of a venture capitalist and what her interests are in investing. She is most excited about crowdsourcing, vertical content and business software-as-a-service. Despite the current recessionary environment,...

Posted in: Venture Perspectives by Scale Venture Partners Tags: biopharmaceutical, emerging biopharmaceutical devices, FDA, Horizon Therapeutics, Lou Bock, Orexigen, Prestwick Pharmaceuticals, Scale Venture Partners, Somaxon, Zogenix